

Table S1 Summary result of regression analysis for model fitting.

Notes: X_1 = TPP (mg/mL), X_2 = Pluronic® F-127 (% w/v), X_3 = HHC (mg/mL), Y_1 = particle size (nm), Y_2 = zeta potential (mV), and Y_3 = EE (%).

Equation:

The equation below explained the physical meaning and significance necessary for the second-order polynomial model used in response surface analysis, given as equations S1-S3.

$$Y = \beta_0 + \beta_1X_1 + \beta_2X_2 + \beta_3X_3 + \beta_{12}X_1X_2 + \beta_{13}X_1X_3 + \beta_{23}X_2X_3 + \beta_{11}X_1^2 + \beta_{22}X_2^2 + \beta_{33}X_3^2$$

Where Y is response (dependent variable), β_0 is intercept, $\beta_1 - \beta_{33}$ are regression coefficients computed from the observed value of Y from experiments, and X_1 , X_2 and X_3 are factors (independent variables). The terms (X_1X_2 , X_1X_3 , and X_2X_3) and (X_1^2 , X_2^2 , and X_3^2) represent the interaction and quadratic terms, respectively [1]. The mathematic model equation was used to evaluate the effect of each factor on the responses and determine the optimum setting of these variables to achieve optimum response [2]. “

Equation:

Equation S1 The multiple linear regression for the response particle size (Y_1)

$$\text{Particle size } (Y_1) = + 239.87 + 84.87X_1 + 56.12X_2 + 17.00X_3$$

Equation S2 The multiple linear regression for the response zeta potential (Y_1)

$$\text{Zeta potential } (Y_2) = + 31.07 - 9.00X_1 - 1.63X_2 - 0.625X_3$$

Equation S3 The multiple linear regression for the response EE (Y_3)

$$\begin{aligned} \text{EE } (Y_3) = & + 75.00 + 10.62X_1 - 3.25X_2 + 14.63X_3 + 2.51X_1X_2 - 1.75X_1X_3 + 1.50X_2X_3 - 1.12X_1^2 - 0.875X_2^2 \\ & - 5.13X_3^2 \end{aligned}$$

Where Y is response, X_1 = TPP (mg/mL), X_2 = Pluronic® F-127 (% w/v), X_3 = HHC (mg/mL), Y_1 = particle size (nm), Y_2 = zeta potential (mV), and Y_3 = EE (%).

References

1. Motwani, S.K.; Chopra, S.; Kohli, T.K.; Ahmad, F.J.; Khar, R.K. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and *in vitro* characterisation. *Eur. J. Pharm. Biopharm*, **2008**, *68* (2008), 513–525. doi: 10.1016/j.ejpb.2007.09.009. Epub 2007 Sep 25.
2. Khuri, A.I.; Mukhopadhyay, S. Response surface methodology. *WIREs Comp Stat*, **2010**, *2*, 128-149. doi.org/10.1002/wics.73.